08:49 AM EDT, 08/28/2025 (MT Newswires) -- Natera ( NTRA ) said Thursday that its Signatera molecular residual disease test has been selected as a secondary endpoint for NRG Oncology's phase 3 study in muscle-invasive bladder cancer.

Signatera will allow researchers to assess real-time circulating-tumor DNA, or ctDNA, clearance patterns as a predictive marker of treatment response and recurrence, according to Natera ( NTRA ).

The company said it will also evaluate urine tumor DNA as an exploratory endpoint.

The study is expected to add to the clinical evidence supporting Signatera in tracking muscle-invasive bladder cancer treatment response and recurrence, Natera ( NTRA ) said.